| First Author | Schriek P | Year | 2022 |
| Journal | Science | Volume | 375 |
| Issue | 6581 | Pages | eabf7470 |
| PubMed ID | 35143312 | Mgi Jnum | J:323813 |
| Mgi Id | MGI:6867096 | Doi | 10.1126/science.abf7470 |
| Citation | Schriek P, et al. (2022) Marginal zone B cells acquire dendritic cell functions by trogocytosis. Science 375(6581):eabf7470 |
| abstractText | Marginal zone (MZ) B cells produce broad-spectrum antibodies that protect against infection early in life. In some instances, antibody production requires MZ B cells to display pathogen antigens bound to major histocompatibility complex class II (MHC II) molecules to T cells. We describe the trogocytic acquisition of these molecules from conventional dendritic cells (cDCs). Complement component 3 (C3) binds to murine and human MHC II on cDCs. MZ B cells recognize C3 with complement receptor 2 (CR2) and trogocytose the MHC II-C3 complexes, which become exposed on their cell surface. The ubiquitin ligase MARCH1 limits the number of MHC II-C3 complexes displayed on cDCs to prevent their elimination through excessive trogocytosis. Capture of C3 by MHC II thus enables the transfer of cDC-like properties to MZ B cells. |
